Radiation-induced Mucositis in Patients with Oropharyngeal Cancer Treated with Moderate Acceleration of Intensity-modulated Radiation Therapy and Simultaneous Integrated Boost Concomitant with Weekly Cisplatin

Lenche Kostadinova; Gjusen  Selim; Petar Chakalaroski; Snezana Smickoska; Marina Stoleska; Danilo Nonkuloski

doi:10.3889/oamjms.2021.5241

Authors

Lenche Kostadinova University Clinic of Radiotherapy and Oncology, Skopje, Republic of Macedonia
Gjusen Selim University Clinic of Nephrology, Skopje, Republic of Macedonia
Petar Chakalaroski University Clinic of Radiotherapy and Oncology, Skopje, Republic of Macedonia
Snezana Smickoska University Clinic of Radiotherapy and Oncology, Skopje, Republic of Macedonia
Marina Stoleska University Clinic of Radiotherapy and Oncology, Skopje, Republic of Macedonia
Danilo Nonkuloski University Clinic for Pediatric Diseases, Skopje, Republic of Macedonia

DOI:

https://doi.org/10.3889/oamjms.2021.5241

Keywords:

IMRT, cancer, mucositis

Abstract

BACKGROUND: Radiation-induced mucositis is one of the limiting factors during radiotherapy, disturbing the quality of life and in some cases leading to discontinuation of therapy. Intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) represents advanced form of radiotherapy technique in treatment of oropharyngeal carcinoma enabling precision cancer targeting with reducing dose to healthy normal tissues.

AIM: The aim of this study was to present maximum grade and duration of a maximum grade of radiation-induced acute mucositis, influence of total volume of oral mucosa, and volumes of oral mucosa which are encompassed by radiation volume of 54 Gy and 66 Gy on the expression of grade of acute mucositis and influence of primary origin of tumor on encompassing with radiation volumes in patients treated with moderate acceleration of IMRT-SIB concomitant weekly cycle of chemotherapy with cisplatin.

MATERIALS AND METHODS: Planned research included 30 patients with oropharyngeal cancer who received their treatment at the University Clinic of Radiotherapy and Oncology in Skopje with moderate acceleration of IMRT-SIB and weekly concomitant cisplatin. Assessment of radiation-induced acute mucositis was performed according to the acute radiation morbidity scoring criteria of the Radiation Therapy Oncology Group.

RESULTS: Maximum grade of acute reaction was confluent mucositis with strong pain and was manifested in 27 patients (90%) with maximum time of duration of 28 days (range 7–28) and median duration of 18 days (range 7–28). Patients, in whom the primary origin of tumor was base of the tongue, a statistically significant difference (p = 0.04) was found for volume of oral mucosa encompassed with PTV66, compared to other localizations of primary oropharyngeal origin. Statistically non-significant difference was found between volume of total oral mucosa and volumes of oral mucosa which are encompassed with radiation volume of 54 Gy and 66 Gy and expression of grade of acute mucositis in the 5th and 6th weeks of radiotherapy.

CONCLUSION: According to these results, recommendations are delineation of oral mucosa as critical structure and implementation of IMRT-SIB to achieve reduction of grade of acute mucositis.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

WHO/NMH/CHP/HPR/ORH. Global Data on Incidence of Oral Cancer, Oral Health Programme, World Health Organization. https://doi.org/10.4314/ajoh.v1i1.31299

Krstevska V, Stojkovski I, Zafirova-Ivanovska B. Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: Analysis of treatment results and prognostic factors. Radiat https://doi.org/10.1186/1748-717x-7-78 PMid:22640662

Pignon J, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355(9208):949-55. https://doi.org/10.1016/s0140-6736(00)90011-4 PMid:10768432

Trotti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47(1):1-12. PMid:10758302

Narayan S, Lehmann J, Coleman M, Vaughan A, Yang C, Enepekides D, et al. Prospective evaluation to establish a dose response for clinical oral mucositis in patients undergoing head-and-neck conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(3):756-62. https://doi.org/10.1016/j.ijrobp.2008.01.060 PMid:18417299

Adelstein D, Li Y, Adams G, Wagner H, Kish J, Ensley J, et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92-8. https://doi.org/10.1200/jco.2003.01.008 PMid:12506176

Krstevska V, Lukarski D, Zafirova-Ivanovska B, Stojkovski I. Acute Mucosal Reactions in Patients with Advanced Head and Neck Cancer Treated with Concurrent Chemoradiotherapy. (Conference). Skopje: Association for Medical Physics and Biomedical Engineering; 2019. Available from: https://www.osti. gov/etdeweb/biblio/21547142. [Last accessed on 2019 Nov 02].

National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology, Head-and-Neck. https://doi.org/10.1002/hed.24866

McQuaid D, Dunlop A, Nill S, Franzese C, Nutting C, Harrington K, et al. Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers: Dosimetry and NTCP. Strahlenther Onkol. 2016;192(8):516-25. https://doi.org/10.1007/s00066-016-0980-1 PMid:27295511

Spiotto M, Weichselbaum R. Comparison of 3D confromal radiotherapy and intensity modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancers. PLoS One. 2014;9(4):e94456. https://doi.org/10.1371/journal.pone.0094456 PMid:24714187

Studer G, Huguenin PU, Davis JB, Kunz G, Lütolf UM, Glanzmann C. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol. 2006;1(1):7. https://doi.org/10.1186/1748-717x-1-7 PMid:16722599

Schwartz M, Vuong T, Ballivy O, Parker W, Patrocinio H. Accelerated radiotherapy with simultaneous integrated boost fractionation and intensity-modulated radiotherapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2007;136(4):549-55. https://doi.org/10.1016/j.otohns.2006.10.044 PMid:17418249

Amin MB, Edge S, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer-Verlag; 2017.

Radiation Therapy Oncology Group RTOG 0022. Phase I/II Study of Conformal and Intensity Modulatet Irradiation for Oropharyngeal Cancer; 2019. Available from: https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails. aspx?study=0022. [Last accessed on 2019 Jun 30].

Krstevska V, Smickoska S. Radioterapija na Kanceri na Glavata i Vratot. Skopje: Medicinski Fakultet; 2015. p. 54-61.

Cox J, Stetz J, Pajak T. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6. https://doi.org/10.1016/0360-3016(95)00060-c PMid:7713792